Peptibodies, compositions thereof, and methods of treating atrial fibrillation
US-2019225658-A1 · Jul 25, 2019 · US
US11617800B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11617800-B2 |
| Application number | US-202017016905-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 10, 2020 |
| Priority date | Sep 12, 2019 |
| Publication date | Apr 4, 2023 |
| Grant date | Apr 4, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K + ) channels to mediate depolarization of cellular membrane potential.
Opening claim text (preview).
What is claimed is: 1. A construct comprising: a gold nanoparticle conjugated to a peptide comprising SEQ ID NO: 1 and a spacer sequence.
from invertebrates · CPC title
the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title
the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient · CPC title
the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title
from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.